CAR-T | GILD Message Board Posts

Gilead Sciences, Inc.

  GILD website

GILD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  11844 of 11887  at  2/7/2019 5:24:14 PM  by

clsm


CAR-T

''Gilead expects to file an IND for an allogeneic anti-CD19 CAR-T therapy (KITE-037) during 2H19
 
BCMA CAR-T program discontinued
 
ZUMA-2: Filing for FDA approval of KTE-X19 in MCL in 2H19
 
ZUMA-3: Completing enrollment in a pivotal phase 2 of KTE-X19 in adult ALL in 2Q19.
 
ZUMA-5: A pivotal phase 2 trial of YESCARTA in r/r indolent NHL, enrollment completed in 1Q19
 
ZUMA-6: A phase 2 trial in combination with a PD-L1 inhibitor, initiated in 1Q18
 
ZUMA-7: A pivotal phase 3 trial in second-line DLBCL''
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 270
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
11845 Re: CAR-T spaddy 0 2/7/2019 8:59:30 PM


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...